Bank of Nova Scotia bought a new position in shares of Chemed Corporation (NYSE:CHE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,300 shares of the company's stock, valued at approximately $7,592,000. Bank of Nova Scotia owned 0.12% of Chemed at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. grew its holdings in Chemed by 2,444,879.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company's stock valued at $2,374,667,000 after buying an additional 5,549,876 shares during the period. BlackRock Inc. purchased a new position in shares of Chemed during the 2nd quarter worth about $691,290,000. JPMorgan Chase & Co. boosted its position in shares of Chemed by 4.4% in the fourth quarter. JPMorgan Chase & Co. now owns 521,900 shares of the company's stock worth $223,301,000 after acquiring an additional 21,932 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Chemed by 89.2% in the fourth quarter. AQR Capital Management LLC now owns 325,579 shares of the company's stock worth $139,302,000 after acquiring an additional 153,469 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in Chemed by 7.5% in the fourth quarter. TD Asset Management Inc now owns 324,546 shares of the company's stock valued at $138,860,000 after purchasing an additional 22,715 shares during the period. 95.85% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Chemed
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the transaction, the chief executive officer directly owned 70,418 shares in the company, valued at $37,991,215.18. This represents a 2.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick P. Grace sold 190 shares of the firm's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director directly owned 3,533 shares of the company's stock, valued at approximately $1,879,556. This represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 6,537 shares of company stock valued at $3,406,014. 3.33% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Oppenheimer upped their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Chemed from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Royal Bank Of Canada upped their price objective on Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a report on Thursday, July 30th. Bank of America reiterated a "neutral" rating on shares of Chemed in a report on Wednesday, July 29th. Finally, Zacks Research raised Chemed from a "strong sell" rating to a "hold" rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $530.75.
Check Out Our Latest Report on Chemed
Chemed Stock Performance
NYSE:CHE opened at $540.18 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The firm has a 50-day moving average of $501.57 and a two-hundred day moving average of $447.26. The stock has a market cap of $7.06 billion, a P/E ratio of 27.13, a PEG ratio of 2.05 and a beta of 0.51. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $557.00.
Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. The business had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The company's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, research analysts expect that Chemed Corporation will post 23.18 earnings per share for the current fiscal year.
Chemed Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Monday, August 17th will be issued a $0.70 dividend. This is a boost from Chemed's previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, August 17th. Chemed's dividend payout ratio is currently 14.06%.
About Chemed
(
Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Read More
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
